In a significant boost to its innovative research capabilities, the Australian Institute for Bioengineering and Nanotechnology (AIBN) has successfully raised $1,300,000 in funding. This financial milestone underscores the institute's commitment to advancing interdisciplinary research at the intersection of bioengineering, nanotechnology, and their diverse applications in human health and environmental issues. AIBN is renowned for its groundbreaking work, including the development of the needleless Nanopatch vaccine delivery device, which is poised to begin human trials. The funding will be allocated to further enhance existing research efforts in several focus areas, such as nanotechnology-based imaging and drug delivery, regenerative medicine, and nanotechnology for energy and environmental applications. In addition, the resources will bolster the AIBN's Industrial Affiliates Program aimed at addressing critical technological challenges faced by the industry. With four active start-up companies birthed from its research initiatives鈥擵axxas Pty Ltd, TenasiTech Pty Ltd, Pepfactants Pty Ltd, and Acyte鈥擜IBN continues to foster an ecosystem of innovation and entrepreneurship. The institute also collaborates with The University of Queensland's commercialisation company, UniQuest, to provide essential support in patent management and business development. This latest funding represents a pivotal step in enhancing AIBN's research landscape, enabling it to propel forward pioneering solutions that could profoundly impact healthcare and environmental sustainability on a global scale.





